World's First Leadless Left Bundle Branch Area Pacing (LBBAP) Surgery Performed Using Abbott's Investigational Aveir CSP System

Cardiologists made history in Prague by performing what is considered to beThe World's First Leadless Left Bundle Branch Area Pacing (LBBAP) Surgery. These procedures were all performed using Abbott's investigational Aveir Conduction System Pacing (CSP) leadless pacemaker system, which falls under the category of includingAveir Dual-Chamber Leadless Pacemaker SystemA part of the same device combination, including.

CSP involves deeply implanting pacemaker leads into the wall that separates the left and right chambers of a patient's heart. This activates the left bundle branch area, mimicking the natural heart rhythm.

‍

Abbott's leadless pacemaker products have achieved considerable success; the Aveir dual-chamber device was approved in July 2023.U.S. Food and Drug Administration (FDA)Approved, released in May 2024The latest dataIndicates that treatment with this device is associated with sustained positive outcomes.

These successful LBBAP procedures are part of a feasibility study aimed at evaluating the safety and effectiveness of the Aveir CSP device. Director of the Cardiology Department at Na Homolce Hospital in Prague, Czech RepublicPetr Neužil, M.D.Ph.D. and Director of Arrhythmia Services at Mount Sinai HospitalVivek Y. Reddy, M.D.Performed this historic surgery with a team of cardiac experts.

Although the Aveir CSP device is currently in the research stage, this data can later be used to help Abbott seek full FDA approval.

"While both conduction system pacing and leadless pacing have offered different benefits to many patients, they have been distinct options – until now," said the director of cardiac electrophysiology at St. Bernard Medical Center in Jonesboro, Arkansas, and a researcher who assisted with the feasibility study.Devi Nair, M.D.Explained in a statement by Abbott.The study on the Aveir CSP leadless pacemaker system is the first to evaluate a pioneering approach that directly targets the left bundle branch area, combining the advantages of conduction system pacing and leadless pacing technology.”

"Bringing our proven leadless pacemaker technology to the left bundle branch area is very likely to become another transformative moment in cardiac care," added Randel Woodgrift, Senior Vice President of Abbott's Rhythm Management Business.